ReviewBone marrow transplantation2021
The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
Review in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.European journal of haematology · 2026Article
- Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.Annals of hematology · 2024Article
- Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.Blood · 2024Article
- External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia.Bone marrow transplantation · 2023Article
- Review
- Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.Annals of hematology · 2023Article
- Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.International journal of hematology · 2023Article
- Treatment for relapsed acute promyelocytic leukemia.Annals of hematology · 2022Review
- FLT3-targeted treatment for acute myeloid leukemia.International journal of hematology · 2022Review
- Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies.Frontiers in oncology · 2022Review
- Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021.Cancers · 2021Review
- Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis.Blood cancer journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-standing debate of whether patients with acute myeloid leukemia (AML) should proceed to allogeneic hematopoietic cell transplantation (HCT) during first complete remission (CR1) remains unsettled. Although allogeneic HCT during CR1 used to be recommended for those with intermediate or poor cytogenetics if they had a matched sibling donor, the concept of indications for allogeneic HCT during CR1 has been evolving by virtue of advances in understanding of the molecular pathogenesis of AML and innovations in transplantation practice attained over the last few decades. The incorporation of molecular profiles of leukemia has been shown to contribute to further refinements of risk classification that had previously relied mostly on cytogenetics, while the progress in transplantation procedures has made it possible to perform transplantations more safely even for patients without a matched sibling donor. These significant changes have underpinned the need to reappraise indications for allogeneic HCT during CR1 of AML. Improvements in clinical applications of genetic and measurable residual disease information as well as in transplantation technology are expected to further refine indications for allogeneic HCT during CR1, and thus promote an individualized approach for the treatment of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.